Physician profile
Claudia Fish
NPI 1043293665
$286,370.45
in general payments reported to CMS, 2019-2025
33 companies · $58K in 2025
The $58K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $16K · 2021: $6,300 · 2022: $45K · 2023: $55K · 2024: $84K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $181K · Travel and Lodging: $11K · Food and Beverage: $4,981 · Honoraria: $325 · Education: $64.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180,775.00 |
| Travel and Lodging | $10,680.08 |
| Food and Beverage | $4,981.42 |
| Honoraria | $325.00 |
| Education | $64.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $237,451.26 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Astrazeneca Pharmaceuticals LP | $44,852.24 | 2019-2024 | Farxiga, Lokelma |
| Novo Nordisk INC | $707.03 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $426.15 | 2019-2024 | Evenity, Prolia, Tepezza |
| Chiesi USA, INC. | $345.68 | 2024-2025 | Mycapssa |
| Sanofi-Aventis U.S. LLC | $266.62 | 2019-2023 | |
| Abbvie INC. | $251.65 | 2019-2024 | |
| Pfizer INC. | $215.54 | 2019-2024 | |
| Horizon Therapeutics Plc | $186.70 | 2020-2023 | Tepezza |
| Merck Sharp & Dohme LLC | $170.37 | 2019-2023 | Steglatro |
| Dexcom, INC. | $117.04 | 2019-2023 | Dexcom G6 Transmitter |
| Radius Health, INC. | $115.45 | 2019-2021 | |
| Amarin Pharma, INC. | $113.44 | 2019-2021 | |
| Insulet Corporation | $111.41 | 2019-2024 | Omnipod |
| Tandem Diabetes Care, INC. | $107.74 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $101.30 | 2019-2022 | |
| Mannkind Corporation | $100.86 | 2019-2020 | |
| Abbott Laboratories | $95.62 | 2019-2024 | Freestyle Libre 3 |
| Medtronic Minimed, INC. | $89.99 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $76.17 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $71.55 | 2022-2023 | |
| Eusa Pharma (US) LLC | $56.57 | 2022 | |
| Nestle Healthcare Nutrition INC. | $47.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.94 | 2019-2021 | |
| Medtronic, INC. | $43.05 | 2021-2022 | |
| Corcept Therapeutics | $42.93 | 2022-2023 | Korlym |
| Madrigal Pharmaceuticals | $41.77 | 2024 | Resmetirom |
| Janssen Pharmaceuticals, INC | $30.82 | 2019 | |
| Ascendis Pharma Endocrinology INC | $26.78 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $18.61 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.61 | 2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $12.61 | 2022 | |
| Lifescan, INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.